CTOs on the Move

Gennao Bio

www.gennao.com

 
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.gennao.com
  • 311 Pennington Rocky Hill Road Building 21
    Hopewell, NJ USA 08534
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Affinia Therapeutics

We are working to methodically engineer durable gene therapies for people with devastating diseases.

Cradle Genomics

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.

Praxis Precision Medicines

Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.

Access BIO

Access BIO is a Boyce, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coherus Biosciences

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team`s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.